Pharmaceutical companies Cipla and Roche India announced on Monday that they will launch a drug mixture containing anti-coronavirus antibodies to treat patients with infections in the community, who are most likely to develop serious infections. Comorbidities such as diabetes and heart, liver and kidney disease.
PTI said the drug is packaged in two doses, and the cost of each dose for the treatment of mild to moderate symptoms is 59,750 rupees. Antibody mixtures (Casirivimab and Imdevimab) are already on the market in India. Cipla and Roche said in a joint statement that the second batch of products will be on the market in mid-June. Overall, they have the potential to benefit 2 million patients because each of the 100,000 packages that India will provide can provide treatment for two patients.
Antibody mixtures are mixtures of two or more unique biological agents that act similarly to human antibodies. Infection control. The statement mentioned that the Pharmaceutical Standards Compliance Organization recently approved the use of antibody mixtures in India in emergency situations. Regeneron Pharmaceuticals, headquartered in York, is imported to India by Roche Pharma and is marketed and distributed through a strategic partnership with Cipla.
Cipla CEO Umang Vohra tweeted about the matter on Twitter on Monday. Vohra said: “It is hoped that this Casirivimab and Imdevimab antibody mixture will bring much-needed relief to patients and medical systems in India.” India is facing a devastating second wave of coronavirus. The tide caused a general shortage of medical oxygen and medicines in Delhi.
On Monday, several other India also reported 222,315 new coronavirus cases, and the number of infections since the beginning of the pandemic has increased to 2,67,52447. In January 2020, the number will range from 4,454 to 3,03,720. After the United States and Brazil, the third-largest country (India) in the world has had more than 300,000 deaths.
Read More:Â Symptoms that one might have of New Strain of Covid-19
